Travere Therapeutics Unveils Promising New Data on FILSPARI® for Rare Kidney Disease at International Podocyte Conference

Reuters

06-11

Travere <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Promising New Data on FILSPARI® for Rare Kidney Disease at International Podocyte Conference

Travere Therapeutics, Inc. (Nasdaq: TVTX) has announced that it will present new data on its drug FILSPARI® (sparsentan) at the 15th International Podocyte Conference in Hamburg, Germany, scheduled for June 10-13, 2025. The company will showcase three abstracts detailing the drug's effects in rare kidney diseases. New findings from the Phase 2 SPARTAN Study indicate that FILSPARI demonstrates antifibrotic and anti-inflammatory properties, impacting B cell and complement pathways in IgA nephropathy (IgAN). The data reveals rapid and sustained reductions in urinary biomarkers associated with disease progression, suggesting potential disease-modifying effects. The presentations will take place on Friday, June 13, 2025, at the Kleiner Festsaal and Small Banquet Hall, covering various aspects of FILSPARI's efficacy in treating kidney-related conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250611309310) on June 11, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542531586"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542531586\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542531586?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-11 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542531586","market":"nz","top_or_hot":-1,"title":"Travere Therapeutics Unveils Promising New Data on FILSPARI® for Rare Kidney Disease at International Podocyte Conference","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Promising New Data on FILSPARI® for Rare Kidney Disease at International Podocyte Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TVTX\">Travere Therapeutics, Inc.</a> (Nasdaq: TVTX) has announced that it will present new data on its drug FILSPARI® (sparsentan) at the 15th International Podocyte Conference in Hamburg, Germany, scheduled for June 10-13, 2025. The company will showcase three abstracts detailing the drug's effects in rare kidney diseases. New findings from the Phase 2 SPARTAN Study indicate that FILSPARI demonstrates antifibrotic and anti-inflammatory properties, impacting B cell and complement pathways in IgA nephropathy (IgAN). The data reveals rapid and sustained reductions in urinary biomarkers associated with disease progression, suggesting potential disease-modifying effects. The presentations will take place on Friday, June 13, 2025, at the Kleiner Festsaal and Small Banquet Hall, covering various aspects of FILSPARI's efficacy in treating kidney-related conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250611309310) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Travere Therapeutics Unveils Promising New Data on FILSPARI® for Rare Kidney Disease at International Podocyte Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTravere Therapeutics Unveils Promising New Data on FILSPARI® for Rare Kidney Disease at International Podocyte Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-11 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Promising New Data on FILSPARI® for Rare Kidney Disease at International Podocyte Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TVTX\">Travere Therapeutics, Inc.</a> (Nasdaq: TVTX) has announced that it will present new data on its drug FILSPARI® (sparsentan) at the 15th International Podocyte Conference in Hamburg, Germany, scheduled for June 10-13, 2025. The company will showcase three abstracts detailing the drug's effects in rare kidney diseases. New findings from the Phase 2 SPARTAN Study indicate that FILSPARI demonstrates antifibrotic and anti-inflammatory properties, impacting B cell and complement pathways in IgA nephropathy (IgAN). The data reveals rapid and sustained reductions in urinary biomarkers associated with disease progression, suggesting potential disease-modifying effects. The presentations will take place on Friday, June 13, 2025, at the Kleiner Festsaal and Small Banquet Hall, covering various aspects of FILSPARI's efficacy in treating kidney-related conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250611309310) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL2c0g0T:1","article_id":"2542531586","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542531586","pubTimestamp":1749639698,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Travere Therapeutics, Inc.  has announced that it will present new data on its drug FILSPARI  at the 15th International Podocyte Conference in Hamburg, Germany, scheduled for June 10-13, 2025. The company will showcase three abstracts detailing the drug's effects in rare kidney diseases. New findings from the Phase 2 SPARTAN Study indicate that FILSPARI demonstrates antifibrotic and anti-inflammatory properties, impacting B cell and complement pathways in IgA nephropathy . The data reveals rapid and sustained reductions in urinary biomarkers associated with disease progression, suggesting potential disease-modifying effects. The presentations will take place on Friday, June 13, 2025, at the Kleiner Festsaal and Small Banquet Hall, covering various aspects of FILSPARI's efficacy in treating kidney-related conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Travere Therapeutics在国际足细胞会议上公布了FILSPARI®治疗罕见肾病的有希望的新数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":0.9},"content_text":"Travere Therapeutics Unveils Promising New Data on FILSPARI® for Rare Kidney Disease at International Podocyte Conference\n    \n\nTravere Therapeutics, Inc. (Nasdaq: TVTX) has announced that it will present new data on its drug FILSPARI® (sparsentan) at the 15th International Podocyte Conference in Hamburg, Germany, scheduled for June 10-13, 2025. The company will showcase three abstracts detailing the drug's effects in rare kidney diseases. New findings from the Phase 2 SPARTAN Study indicate that FILSPARI demonstrates antifibrotic and anti-inflammatory properties, impacting B cell and complement pathways in IgA nephropathy (IgAN). The data reveals rapid and sustained reductions in urinary biomarkers associated with disease progression, suggesting potential disease-modifying effects. The presentations will take place on Friday, June 13, 2025, at the Kleiner Festsaal and Small Banquet Hall, covering various aspects of FILSPARI's efficacy in treating kidney-related conditions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250611309310) on June 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}